



Clinical trial results:

A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)

Summary

EudraCT number	2010-020065-24
Trial protocol	GB HU LV BE AT LT CZ DE ES NL GR IT
Global end of trial date	25 March 2016

Results information

Result version number	v1 (current)
This version publication date	29 June 2017
First version publication date	29 June 2017

Trial information

Trial identification

Sponsor protocol code	WA25204
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Hoffmann-La Roche
Sponsor organisation address	Grenzacherstrasse 124, Basel,, Switzerland,
Public contact	Medical Communications, Hoffmann-La Roche, genentech@druginfo.com
Scientific contact	Medical Communications, Hoffmann-La Roche, genentech@druginfo.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 March 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 March 2016
Global end of trial reached?	Yes
Global end of trial date	25 March 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to compare prospectively in patients treated with TCZ or ETA, the time to first occurrence of any component of the composite of:

- Cardiovascular (CV) death
- Non-fatal myocardial infarction (MI)
- Non-fatal stroke of all classifications (ischemic, hemorrhagic, or undetermined origin)

Protection of trial subjects:

The study was conducted in accordance with the principles of the "Declaration of Helsinki" and Good Clinical Practice. Approval from the Independent Ethics Committee/Institutional Review Board was obtained before study start and was documented in a letter to the Investigator specifying the date on which the committee met and granted the approval.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 August 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 313
Country: Number of subjects enrolled	Austria: 10
Country: Number of subjects enrolled	Belgium: 15
Country: Number of subjects enrolled	Bosnia and Herzegovina: 58
Country: Number of subjects enrolled	Canada: 79
Country: Number of subjects enrolled	Chile: 124
Country: Number of subjects enrolled	Czech Republic: 206
Country: Number of subjects enrolled	Germany: 65
Country: Number of subjects enrolled	Ecuador: 40
Country: Number of subjects enrolled	Spain: 88
Country: Number of subjects enrolled	France: 11
Country: Number of subjects enrolled	United Kingdom: 62
Country: Number of subjects enrolled	Greece: 14
Country: Number of subjects enrolled	Croatia: 40
Country: Number of subjects enrolled	Hungary: 54
Country: Number of subjects enrolled	India: 31
Country: Number of subjects enrolled	Italy: 18

Country: Number of subjects enrolled	Lithuania: 38
Country: Number of subjects enrolled	Latvia: 41
Country: Number of subjects enrolled	Mexico: 335
Country: Number of subjects enrolled	Malaysia: 18
Country: Number of subjects enrolled	Netherlands: 4
Country: Number of subjects enrolled	Philippines: 21
Country: Number of subjects enrolled	Poland: 215
Country: Number of subjects enrolled	Romania: 149
Country: Number of subjects enrolled	Russian Federation: 206
Country: Number of subjects enrolled	Serbia: 64
Country: Number of subjects enrolled	Turkey: 10
Country: Number of subjects enrolled	United States: 671
Country: Number of subjects enrolled	South Africa: 59
Country: Number of subjects enrolled	Israel: 21
Worldwide total number of subjects	3080
EEA total number of subjects	1030

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	2182
From 65 to 84 years	895
85 years and over	3

Subject disposition

Recruitment

Recruitment details:

A total of 3080 patients were enrolled from 353 sites, across 31 countries

Pre-assignment

Screening details:

The target population was patients with moderate to severe rheumatoid arthritis ≥ 6 months duration and for whom non-biologic DMARD treatment or treatment with an anti-tumor necrosis factor (anti-TNF) agent was inadequate.

Patients were required to be 50 years or older and to have at least one additional CV risk factor beyond RA.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Tocilizumab

Arm description:

Participants received 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.

Arm type	Experimental
Investigational medicinal product name	Tocilizumab
Investigational medicinal product code	
Other name	RoActemra, Actemra, RO4877533
Pharmaceutical forms	Solution for injection/infusion in pre-filled syringe
Routes of administration	Intravenous use

Dosage and administration details:

Tocilizumab was administered at a dose of 8 mg/kg every 4 weeks.

Arm title	Etanercept
------------------	------------

Arm description:

Participants received 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.

Arm type	Active comparator
Investigational medicinal product name	Etanercept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received 50 mg etanercept subcutaneously weekly

Number of subjects in period 1	Tocilizumab	Etanercept
Started	1538	1542
Completed	1482	1475
Not completed	56	67
Adverse event, serious fatal	30	34
Consent withdrawn by subject	13	16
Info not recorded	10	16
Lost to follow-up	3	1

Baseline characteristics

Reporting groups

Reporting group title	Tocilizumab
Reporting group description:	
Participants received 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.	
Reporting group title	Etanercept
Reporting group description:	
Participants received 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.	

Reporting group values	Tocilizumab	Etanercept	Total
Number of subjects	1538	1542	3080
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	1095	1087	2182
From 65-84 years	441	454	895
85 years and over	2	1	3
Age Continuous			
Units: Years			
arithmetic mean	60.7	60.7	
standard deviation	± 7.4	± 7.6	-
Gender, Male/Female			
Units: Participants			
Female	1193	1202	2395
Male	345	340	685

End points

End points reporting groups

Reporting group title	Tocilizumab
Reporting group description: Participants received 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.	
Reporting group title	Etanercept
Reporting group description: Participants received 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.	

Primary: Time to first Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event

End point title	Time to first Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event
End point description: Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke. Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.	
End point type	Primary
End point timeframe: Baseline up to 4.9 years	

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentage of patients with event				
number (not applicable)	5.4	5.1		

Statistical analyses

Statistical analysis title	Cox Regression
Statistical analysis description: The analysis assessed in the ITT population the hazard ratio of the primary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients. A stratified Cox proportional hazards regression model was used in evaluating the relative MACE rate of TCZ over ETA, with the following randomization factors used as strata: • Previous exposure to anti-TNF (Yes/No) • History of CV events (Yes/No)	
Comparison groups	Tocilizumab v Etanercept

Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Hazard ratio (HR)
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.43

Primary: Time to first CV-EAC Adjudicated Event - Sensitivity Analysis

End point title	Time to first CV-EAC Adjudicated Event - Sensitivity Analysis
End point description:	
Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analysis. Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.	
End point type	Primary
End point timeframe:	
From Baseline up to 4.9 years	

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentage of patients with event				
number (not applicable)	3.7	3.4		

Statistical analyses

Statistical analysis title	Cox regression
Statistical analysis description:	
The analysis assessed in the OT population the hazard ratio of the primary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients. A stratified Cox proportional hazards regression model was used in evaluating the relative MACE rate of TCZ over ETA, with the following randomization factors used as strata: • Previous exposure to anti-TNF (Yes/No) • History of CV events (Yes/No)	
Comparison groups	Tocilizumab v Etanercept
Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Hazard ratio (HR)
Point estimate	1.11

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.62

Primary: Time to first CV-EAC adjudicated event excluding undetermined cause of death - Sensitivity Analysis

End point title	Time to first CV-EAC adjudicated event excluding undetermined cause of death - Sensitivity Analysis
End point description:	
Prospective comparison of time to first occurrence of any component of the composite of CV death (excluding events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke - Sensitivity Analyses. Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.	
End point type	Primary
End point timeframe:	
From baseline up to 4.9 years	

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentage of patients with an event				
number (not applicable)	4.8	4.7		

Statistical analyses

Statistical analysis title	Cox regression
Statistical analysis description:	
The analysis assessed in the ITT population the hazard ratio of the primary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients. A stratified Cox proportional hazards regression model was used in evaluating the relative MACE rate of TCZ over ETA, with the following randomization factors used as strata: • Previous exposure to anti-TNF (Yes/No) • History of CV events (Yes/No)	
Comparison groups	Tocilizumab v Etanercept
Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Hazard ratio (HR)
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.4

Primary: Time to first CV-EAC adjudicated event before last direct contact date - Sensitivity Analysis

End point title	Time to first CV-EAC adjudicated event before last direct contact date - Sensitivity Analysis
-----------------	---

End point description:

Prospective comparison of time to first occurrence of any component of the composite of CV death (including events adjudicated as 'Undetermined Cause of Death'), non-fatal myocardial infarction, or non-fatal stroke before last direct contact date (i.e., latest date of visit, IVRS call, or site call). Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.

End point type	Primary
----------------	---------

End point timeframe:

From Baseline up to 4.9 years

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentage of participants with an event				
number (not applicable)	3.2	3		

Statistical analyses

Statistical analysis title	Cox regression
----------------------------	----------------

Statistical analysis description:

The analysis assessed in the ITT population the hazard ratio of the primary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients. A stratified Cox proportional hazards regression model was used in evaluating the relative MACE rate of TCZ over ETA, with the following randomization factors used as strata: • Previous exposure to anti-TNF (Yes/No) • History of CV events (Yes/No)

Comparison groups	Tocilizumab v Etanercept
Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Hazard ratio (HR)
Point estimate	1.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.56

Secondary: The time to first occurrence of an expanded CV composite endpoint

End point title	The time to first occurrence of an expanded CV composite endpoint
End point description: Prospective comparison of the time to first occurrence of the expanded composite endpoint. The expanded composite endpoint is defined as the CV composite of the primary endpoint with the addition of non-elective coronary revascularization procedures and hospitalization for unstable angina. Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.	
End point type	Secondary
End point timeframe: From baseline up to 4.9 years	

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentages of participants				
number (not applicable)	5.5	5.4		

Statistical analyses

Statistical analysis title	Cox regression
Statistical analysis description: The analysis assessed in the ITT population the hazard ratio of the secondary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients. A stratified Cox proportional hazards regression model was used in evaluating the relative CV event rate of TCZ over ETA, with the following randomization factors used as strata: <ul style="list-style-type: none"> • Previous exposure to anti-TNF (Yes/No) • History of CV events (Yes/No) 	
Comparison groups	Tocilizumab v Etanercept
Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
Parameter estimate	Hazard ratio (HR)
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.34

Notes:

[1] - The non-inferiority margin was only formally tested for the primary ITT analysis

Secondary: Individual component of primary endpoint: Non-fatal Myocardial Infarction

End point title	Individual component of primary endpoint: Non-fatal Myocardial Infarction
End point description: Prospective comparison of time to first occurrence of Individual component of primary endpoint: Non	

fatal Myocardial Infarction.

Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.

End point type	Secondary
End point timeframe:	
From baseline up to 4.9 years	

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentage of participants				
number (not applicable)	1.8	2		

Statistical analyses

Statistical analysis title	Cox regression
----------------------------	----------------

Statistical analysis description:

The analysis assessed in the ITT population the hazard ratio of the secondary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients.

A stratified Cox proportional hazards regression model was used in evaluating the relative CV event rate of TCZ over ETA, with the following randomization factors used as strata:

- Previous exposure to anti-TNF (Yes/No)
- History of CV events (Yes/No)

Comparison groups	Tocilizumab v Etanercept
Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[2]
Parameter estimate	Hazard ratio (HR)
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.49

Notes:

[2] - The non-inferiority margin was only formally tested for the primary ITT analysis

Secondary: Individual component of primary endpoint: cardiovascular death

End point title	Individual component of primary endpoint: cardiovascular death
-----------------	--

End point description:

Prospective comparison of time to first occurrence of Individual component of primary endpoint: cardiovascular death.

Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.

End point type	Secondary
End point timeframe:	
From baseline up to 4.9 years	

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentage of participants				
number (not applicable)	2.3	2.3		

Statistical analyses

Statistical analysis title	Cox regression
----------------------------	----------------

Statistical analysis description:

The analysis assessed in the ITT population the hazard ratio of the secondary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients.

A stratified Cox proportional hazards regression model was used in evaluating the relative CV event rate of TCZ over ETA, with the following randomization factors used as strata:

- Previous exposure to anti-TNF (Yes/No)
- History of CV events (Yes/No)

Comparison groups	Tocilizumab v Etanercept
Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[3]
Parameter estimate	Hazard ratio (HR)
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	1.63

Notes:

[3] - The non-inferiority margin was only formally tested for the primary ITT analysis.

Secondary: Individual component of primary endpoint: non-fatal stroke

End point title	Individual component of primary endpoint: non-fatal stroke
-----------------	--

End point description:

Prospective comparison of time to first occurrence of Individual component of primary endpoint: non-fatal stroke.

Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline up to 4.9 years

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentage of participants with an event				
number (not applicable)	1.6	1		

Statistical analyses

Statistical analysis title	Cox regression
Statistical analysis description:	
<p>The analysis assessed in the ITT population the hazard ratio of the secondary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients.</p> <p>A stratified Cox proportional hazards regression model was used in evaluating the relative CV event rate of TCZ over ETA, with the following randomization factors used as strata:</p> <ul style="list-style-type: none"> • Previous exposure to anti-TNF (Yes/No) • History of CV events (Yes/No) 	
Comparison groups	Tocilizumab v Etanercept
Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[4]
Parameter estimate	Hazard ratio (HR)
Point estimate	1.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	2.92

Notes:

[4] - The non-inferiority margin was only formally tested for the primary ITT analysis

Secondary: Individual component of primary endpoint: All-cause mortality

End point title	Individual component of primary endpoint: All-cause mortality
End point description:	
<p>Prospective comparison of time to first occurrence of Individual component of primary endpoint: All-cause mortality.</p> <p>Median time to event and 95% confidence intervals could not be estimated due to less than 50% of patients experiencing an event; percentage of patients with event is reported.</p>	
End point type	Secondary
End point timeframe:	
From baseline up to 4.9 years	

End point values	Tocilizumab	Etanercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1538	1542		
Units: Percentage of participants				
number (not applicable)	4.2	4.2		

Statistical analyses

Statistical analysis title	Cox regression
----------------------------	----------------

Statistical analysis description:

The analysis assessed in the ITT population the hazard ratio of the secondary endpoint in TCZ compared to ETA patients. This was done through a comparison of the hazard functions between TCZ and ETA patients.

A stratified Cox proportional hazards regression model was used in evaluating the relative CV event rate of TCZ over ETA, with the following randomization factors used as strata:

- Previous exposure to anti-TNF (Yes/No)
- History of CV events (Yes/No)

Comparison groups	Tocilizumab v Etanercept
Number of subjects included in analysis	3080
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[5]
Parameter estimate	Hazard ratio (HR)
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.41

Notes:

[5] - The non-inferiority margin was only formally tested for the primary ITT analysis.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected throughout the entire course of the study.

Adverse event reporting additional description:

Analyses were conducted on the On treatment safety (OTS) population.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	Etanercept
-----------------------	------------

Reporting group description:

Participants received 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.

Reporting group title	Tocilizumab
-----------------------	-------------

Reporting group description:

Participants received 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.

Serious adverse events	Etanercept	Tocilizumab	
Total subjects affected by serious adverse events			
subjects affected / exposed	422 / 1542 (27.37%)	479 / 1538 (31.14%)	
number of deaths (all causes)	69	67	
number of deaths resulting from adverse events	10	14	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
ADENOCARCINOMA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ADENOCARCINOMA OF COLON			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANAL SQUAMOUS CELL CARCINOMA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

BASAL CELL CARCINOMA			
subjects affected / exposed	3 / 1542 (0.19%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 5	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BENIGN ANORECTAL NEOPLASM			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BENIGN NEOPLASM OF CERVIX UTERI			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BLADDER CANCER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
BLADDER TRANSITIONAL CELL CARCINOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRAIN NEOPLASM			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
BREAST CANCER			
subjects affected / exposed	3 / 1542 (0.19%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	1 / 3	2 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
CARCINOID TUMOUR OF THE GASTROINTESTINAL TRACT			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

CARCINOID TUMOUR PULMONARY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC MYXOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CENTRAL NERVOUS SYSTEM LYMPHOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CEREBRAL HAEMANGIOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLANGIOCARCINOMA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
COLON ADENOMA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLON CANCER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLON CANCER METASTATIC			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
COLORECTAL CANCER			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIFFUSE LARGE B–CELL LYMPHOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENDOMETRIAL ADENOCARCINOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GLIOBLASTOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMANGIOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTESTINAL ADENOCARCINOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTRADUCTAL PROLIFERATIVE BREAST LESION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LARYNGEAL CANCER			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG ADENOCARCINOMA			

subjects affected / exposed	1 / 1542 (0.06%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	1 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
LUNG ADENOCARCINOMA STAGE IV			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
LUNG CANCER METASTATIC			
subjects affected / exposed	2 / 1542 (0.13%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
LUNG NEOPLASM			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
LUNG NEOPLASM MALIGNANT			
subjects affected / exposed	4 / 1542 (0.26%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 4	1 / 3	
deaths causally related to treatment / all	0 / 2	1 / 3	
MALIGNANT MELANOMA STAGE II			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MARJOLIN'S ULCER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTASES TO BONE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTATIC GASTRIC CANCER			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
METASTATIC NEOPLASM			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
NEOPLASM MALIGNANT			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NON-HODGKIN'S LYMPHOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OVARIAN ADENOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OVARIAN CANCER			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
PANCREATIC CARCINOMA METASTATIC			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
PANCREATIC NEOPLASM			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
PAPILLARY THYROID CANCER			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PARAPROTEINAEMIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PARATHYROID TUMOUR BENIGN			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PHARYNGEAL NEOPLASM BENIGN			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PITUITARY TUMOUR BENIGN			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLASMA CELL MYELOMA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PROSTATE CANCER			
subjects affected / exposed	1 / 1542 (0.06%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL CANCER			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL CELL CARCINOMA			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SMALL CELL LUNG CANCER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SQUAMOUS CELL CARCINOMA OF LUNG			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SQUAMOUS CELL CARCINOMA OF THE TONGUE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SQUAMOUS ENDOMETRIAL CARCINOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
THYROID ADENOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TUMOUR INVASION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

UTERINE CANCER			
subjects affected / exposed	0 / 1542 (0.00%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vascular disorders			
AORTIC ANEURYSM			
subjects affected / exposed	4 / 1542 (0.26%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
AORTIC ANEURYSM RUPTURE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
AORTIC CALCIFICATION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
AORTIC DISSECTION			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
AORTIC STENOSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEEP VEIN THROMBOSIS			
subjects affected / exposed	8 / 1542 (0.52%)	6 / 1538 (0.39%)	
occurrences causally related to treatment / all	0 / 8	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
EMBOLISM ARTERIAL			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMORAL ARTERY EMBOLISM			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATOMA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSION			
subjects affected / exposed	6 / 1542 (0.39%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSIVE CRISIS			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSIVE EMERGENCY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOTENSION			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFARCTION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE			

subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL ISCHAEMIA			
subjects affected / exposed	2 / 1542 (0.13%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL VENOUS DISEASE			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
RHEUMATOID VASCULITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBCLAVIAN ARTERY OCCLUSION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
THROMBOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
VARICOSE VEIN			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VENOUS THROMBOSIS LIMB			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
ABDOMINAL HERNIA REPAIR			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANAL FISTULA EXCISION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANGIOPLASTY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
APPENDICECTOMY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC PACEMAKER REPLACEMENT			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLOSTOMY CLOSURE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIP ARTHROPLASTY			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
IMPLANTABLE DEFIBRILLATOR INSERTION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
KNEE ARTHROPLASTY			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LARGE INTESTINE ANASTOMOSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MITRAL VALVE REPLACEMENT			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEQUESTRECTOMY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
UMBILICAL HERNIA REPAIR			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
CHEST PAIN			
subjects affected / exposed	10 / 1542 (0.65%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 10	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
COMPLICATION ASSOCIATED WITH DEVICE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEATH			
subjects affected / exposed	4 / 1542 (0.26%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 4	0 / 3	
GENERAL PHYSICAL HEALTH			

DETERIORATION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
IMPAIRED HEALING			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOCAL SWELLING			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MULTIPLE ORGAN DYSFUNCTION SYNDROME			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	1 / 1542 (0.06%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
OEDEMA PERIPHERAL			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAIN			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
PYREXIA			
subjects affected / exposed	3 / 1542 (0.19%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	1 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUDDEN DEATH			

subjects affected / exposed	1 / 1542 (0.06%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 3	
SWELLING			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Immune system disorders			
DRUG HYPERSENSITIVITY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERSENSITIVITY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OVERLAP SYNDROME			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SARCOIDOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
ACQUIRED PHIMOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BREAST FIBROSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

CERVICAL POLYP			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CERVICAL DYSPLASIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CYSTOCELE			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
GENITAL PROLAPSE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
METRORRHAGIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OVARIAN CYST			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OVARIAN CYST TORSION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPERMATOCELE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RECTOCELE			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
UTERINE POLYP			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
UTERINE PROLAPSE			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VAGINAL HAEMATOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
ACUTE PULMONARY OEDEMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE RESPIRATORY DISTRESS SYNDROME			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
ACUTE RESPIRATORY FAILURE			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ALVEOLITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASTHMA			

subjects affected / exposed	5 / 1542 (0.32%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 7	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASTHMATIC CRISIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATELECTASIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHIAL HYPERREACTIVITY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHIAL OBSTRUCTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHITIS CHRONIC			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHOSPASM			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHOSTENOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			

subjects affected / exposed	7 / 1542 (0.45%)	10 / 1538 (0.65%)	
occurrences causally related to treatment / all	2 / 7	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 2	
CHRONIC RESPIRATORY FAILURE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSпноEA			
subjects affected / exposed	4 / 1542 (0.26%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	0 / 4	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
EMPHYSEMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
EPISTAXIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYDROTHORAX			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOXIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTERSTITIAL LUNG DISEASE			
subjects affected / exposed	3 / 1542 (0.19%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	1 / 3	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG DISORDER			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG INFILTRATION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLEURAL EFFUSION			
subjects affected / exposed	5 / 1542 (0.32%)	6 / 1538 (0.39%)	
occurrences causally related to treatment / all	0 / 6	1 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONIA ASPIRATION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMOTHORAX			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY EMBOLISM			
subjects affected / exposed	11 / 1542 (0.71%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	2 / 11	0 / 1	
deaths causally related to treatment / all	1 / 2	0 / 0	
PULMONARY FIBROSIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
PULMONARY GRANULOMA			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY HYPERTENSION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY MASS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY OEDEMA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY SARCOIDOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY THROMBOSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
RESPIRATORY DISTRESS			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
RESPIRATORY FAILURE			
subjects affected / exposed	6 / 1542 (0.39%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	2 / 6	0 / 1	
deaths causally related to treatment / all	1 / 3	0 / 0	
Psychiatric disorders			
BURNOUT SYNDROME			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONFUSIONAL STATE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DELIRIUM			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DELIRIUM TREMENS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEPRESSION			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MAJOR DEPRESSION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MENTAL DISORDER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PSYCHOTIC DISORDER			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SCHIZOAFFECTIVE DISORDER BIPOLAR TYPE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUICIDAL IDEATION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUICIDE ATTEMPT			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MANIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
DEVICE BREAKAGE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE DISLOCATION			
subjects affected / exposed	0 / 1542 (0.00%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE FAILURE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE LOOSENING			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
BILE DUCT OBSTRUCTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLANGITIS ACUTE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLECYSTITIS			
subjects affected / exposed	0 / 1542 (0.00%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLECYSTITIS ACUTE			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLECYSTITIS CHRONIC			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLELITHIASIS			
subjects affected / exposed	6 / 1542 (0.39%)	14 / 1538 (0.91%)	
occurrences causally related to treatment / all	0 / 6	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATIC VEIN THROMBOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATITIS			

subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATITIS ACUTE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST CHOLECYSTECTOMY SYNDROME			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
EOSINOPHIL COUNT INCREASED			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATOCRIT ABNORMAL			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMOGLOBIN ABNORMAL			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LIVER FUNCTION TEST INCREASED			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STAPHYLOCOCCUS TEST POSITIVE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SYNOVIAL FLUID WHITE BLOOD CELLS POSITIVE			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRANSAMINASES INCREASED			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TROPONIN INCREASED			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
ACCIDENT AT WORK			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
ANAEMIA POSTOPERATIVE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANKLE FRACTURE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHROPOD STING			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
COMMINUTED FRACTURE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONTUSION			

subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DISLOCATION OF VERTEBRA			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
FALL			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMORAL NECK FRACTURE			
subjects affected / exposed	3 / 1542 (0.19%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMUR FRACTURE			
subjects affected / exposed	6 / 1542 (0.39%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
FOOT FRACTURE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FRACTURE DISPLACEMENT			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GUN SHOT WOUND			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
HAND FRACTURE			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIP FRACTURE			
subjects affected / exposed	12 / 1542 (0.78%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	0 / 12	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
HUMERUS FRACTURE			
subjects affected / exposed	4 / 1542 (0.26%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFUSION RELATED REACTION			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
JOINT DISLOCATION			
subjects affected / exposed	2 / 1542 (0.13%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
JOINT INJURY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LIGAMENT INJURY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOWER LIMB FRACTURE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OVERDOSE			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PATELLA FRACTURE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMOTHORAX TRAUMATIC			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL FISTULA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL HAEMATOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RADIUS FRACTURE			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
RESPIRATORY FUME INHALATION DISORDER			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RIB FRACTURE			
subjects affected / exposed	4 / 1542 (0.26%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL COMPRESSION FRACTURE			

subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL FRACTURE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STOMAL HERNIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STRESS FRACTURE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBCUTANEOUS HAEMATOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBDURAL HAEMATOMA			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
SYNOVIAL RUPTURE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TENDON RUPTURE			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
THORACIC VERTEBRAL FRACTURE			

subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ULNA FRACTURE			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
UPPER LIMB FRACTURE			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
WOUND			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
WOUND DEHISCENCE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
WRIST FRACTURE			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
ATRIAL SEPTAL DEFECT			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYDROCELE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			

ACUTE CORONARY SYNDROME			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	9 / 1542 (0.58%)	7 / 1538 (0.46%)	
occurrences causally related to treatment / all	1 / 9	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
ADAMS–STOKES SYNDROME			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANGINA PECTORIS			
subjects affected / exposed	2 / 1542 (0.13%)	8 / 1538 (0.52%)	
occurrences causally related to treatment / all	1 / 2	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANGINA UNSTABLE			
subjects affected / exposed	7 / 1542 (0.45%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	0 / 10	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIAL FIBRILLATION			
subjects affected / exposed	18 / 1542 (1.17%)	14 / 1538 (0.91%)	
occurrences causally related to treatment / all	3 / 23	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIAL FLUTTER			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIOVENTRICULAR BLOCK SECOND DEGREE			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRADYARRHYTHMIA			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRADYCARDIA			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BUNDLE BRANCH BLOCK LEFT			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC ARREST			
subjects affected / exposed	4 / 1542 (0.26%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 4	0 / 1	
CARDIAC FAILURE			
subjects affected / exposed	3 / 1542 (0.19%)	11 / 1538 (0.72%)	
occurrences causally related to treatment / all	0 / 3	5 / 16	
deaths causally related to treatment / all	0 / 1	1 / 3	
CARDIAC FAILURE CHRONIC			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
CARDIAC FAILURE CONGESTIVE			
subjects affected / exposed	8 / 1542 (0.52%)	7 / 1538 (0.46%)	
occurrences causally related to treatment / all	2 / 11	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 1	
CARDIAC FIBRILLATION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC TAMPONADE			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIOGENIC SHOCK			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIOMYOPATHY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIOPULMONARY FAILURE			
subjects affected / exposed	1 / 1542 (0.06%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 4	
CORONARY ARTERY DISEASE			
subjects affected / exposed	3 / 1542 (0.19%)	9 / 1538 (0.59%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
CORONARY ARTERY OCCLUSION			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
CORONARY ARTERY STENOSIS			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSIVE HEART DISEASE			
subjects affected / exposed	0 / 1542 (0.00%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
ISCHAEMIC CARDIOMYOPATHY			

subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LEFT VENTRICULAR FAILURE			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
MITRAL VALVE INCOMPETENCE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MITRAL VALVE STENOSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYOCARDIAL INFARCTION			
subjects affected / exposed	15 / 1542 (0.97%)	10 / 1538 (0.65%)	
occurrences causally related to treatment / all	2 / 15	0 / 10	
deaths causally related to treatment / all	1 / 5	0 / 1	
MYOCARDIAL ISCHAEMIA			
subjects affected / exposed	3 / 1542 (0.19%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
PALPITATIONS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POSTINFARCTION ANGINA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SILENT MYOCARDIAL INFARCTION			

subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SINOATRIAL BLOCK			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SINUS BRADYCARDIA			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SINUS NODE DYSFUNCTION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUPRAVENTRICULAR TACHYCARDIA			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TACHYCARDIA			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VENTRICULAR DYSFUNCTION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VENTRICULAR FIBRILLATION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VENTRICULAR TACHYCARDIA			

subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIO-RESPIRATORY ARREST			
subjects affected / exposed	3 / 1542 (0.19%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	1 / 3	0 / 1	
Nervous system disorders			
AMYOTROPHIC LATERAL SCLEROSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BALANCE DISORDER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRAIN STEM INFARCTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CAROTID ARTERY DISEASE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CAROTID ARTERY STENOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CEREBRAL HAEMATOMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CEREBRAL INFARCTION			

subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CEREBRAL ISCHAEMIA			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CEREBROVASCULAR ACCIDENT			
subjects affected / exposed	8 / 1542 (0.52%)	14 / 1538 (0.91%)	
occurrences causally related to treatment / all	0 / 8	2 / 15	
deaths causally related to treatment / all	0 / 3	1 / 3	
CEREBROVASCULAR DISORDER			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CERVICAL CORD COMPRESSION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CERVICAL RADICULOPATHY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COMA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
DEMENTIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEMENTIA ALZHEIMER'S TYPE			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
DIABETIC COMA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSARTHRIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSKINESIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
EMBOLIC STROKE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENCEPHALOPATHY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
EPILEPSY			
subjects affected / exposed	0 / 1542 (0.00%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
FACIAL PARALYSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GENERALISED TONIC–CLONIC SEIZURE			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMORRHAGIC STROKE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
HEMIPARESIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATIC ENCEPHALOPATHY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSIVE ENCEPHALOPATHY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTRACRANIAL ANEURYSM			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ISCHAEMIC STROKE			
subjects affected / exposed	5 / 1542 (0.32%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	0 / 5	1 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
LOSS OF CONSCIOUSNESS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUMBAR RADICULOPATHY			

subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
METABOLIC ENCEPHALOPATHY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MIGRAINE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYASTHENIA GRAVIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PARAESTHESIA			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PARKINSON'S DISEASE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PRESYNCOPE			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
REVERSIBLE ISCHAEMIC NEUROLOGICAL DEFICIT			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RUPTURED CEREBRAL ANEURYSM			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SCIATICA			
subjects affected / exposed	3 / 1542 (0.19%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEIZURE			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL CORD COMPRESSION			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
SUBARACHNOID HAEMORRHAGE			
subjects affected / exposed	3 / 1542 (0.19%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
SYNCOPE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRANSIENT GLOBAL AMNESIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRANSIENT ISCHAEMIC ATTACK			
subjects affected / exposed	3 / 1542 (0.19%)	9 / 1538 (0.59%)	
occurrences causally related to treatment / all	0 / 3	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULAR DEMENTIA			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	9 / 1542 (0.58%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
AUTOIMMUNE HAEMOLYTIC ANAEMIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COAGULOPATHY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GRANULOCYTOPENIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LEUKOCYTOSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MICROCYTIC ANAEMIA			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCYTOPENIA			
subjects affected / exposed	4 / 1542 (0.26%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
THROMBOCYTOPENIA			

subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
LEUKOPENIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
DEAFNESS UNILATERAL			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VERTIGO			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
CATARACT			
subjects affected / exposed	2 / 1542 (0.13%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
CORNEAL PERFORATION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
KERATITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RETINAL ARTERY OCCLUSION			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RETINAL DETACHMENT			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SCLERITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ULCERATIVE KERATITIS			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
ABDOMINAL ADHESIONS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL HERNIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL PAIN			
subjects affected / exposed	4 / 1542 (0.26%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 4	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACID PEPTIC DISEASE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE ABDOMEN			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
ASCITES			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLITIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLITIS ISCHAEMIC			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLITIS ULCERATIVE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONSTIPATION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CROHN'S DISEASE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIAPHRAGMATIC HERNIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIARRHOEA			

subjects affected / exposed	4 / 1542 (0.26%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	1 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULAR PERFORATION			
subjects affected / exposed	1 / 1542 (0.06%)	6 / 1538 (0.39%)	
occurrences causally related to treatment / all	0 / 1	6 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULUM			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULUM INTESTINAL			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULUM INTESTINAL HAEMORRHAGIC			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DUODENAL ULCER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTERITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTEROCOLITIS			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMORAL HERNIA			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRIC ULCER HAEMORRHAGE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRIC ULCER			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRIC ULCER PERFORATION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRITIS			
subjects affected / exposed	2 / 1542 (0.13%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	4 / 1542 (0.26%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	0 / 4	1 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
GASTRITIS HAEMORRHAGIC			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL INFLAMMATION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL ULCER HAEMORRHAGE			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROOESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATEMESIS			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	1 / 1	
HAEMATOCHYZIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INCARCERATED HIATUS HERNIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMORRHOIDS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INCARCERATED UMBILICAL HERNIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INGUINAL HERNIA			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTESTINAL OBSTRUCTION			

subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LARGE INTESTINAL STENOSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LARGE INTESTINE PERFORATION			
subjects affected / exposed	0 / 1542 (0.00%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	0 / 0	3 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
LARGE INTESTINE POLYP			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOWER GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MALLORY–WEISS SYNDROME			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MELAENA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NAUSEA			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
OESOPHAGITIS			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PALATAL DISORDER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCREATITIS			
subjects affected / exposed	1 / 1542 (0.06%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	0 / 1	3 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCREATITIS ACUTE			
subjects affected / exposed	3 / 1542 (0.19%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	0 / 5	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
PEPTIC ULCER			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PEPTIC ULCER HAEMORRHAGE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
RETROPERITONEAL FIBROSIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
UPPER GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	2 / 1542 (0.13%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
VOMITING			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
ANGIOEDEMA			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BLISTER			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DECUBITUS ULCER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DERMAL CYST			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DERMATITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETIC FOOT			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERSENSITIVITY VASCULITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
PEMPHIGOID			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RASH			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RASH ERYTHEMATOUS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SKIN DISORDER			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SKIN NECROSIS			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SKIN ULCER			
subjects affected / exposed	1 / 1542 (0.06%)	4 / 1538 (0.26%)	
occurrences causally related to treatment / all	1 / 1	2 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
URTICARIA			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULITIC ULCER			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
ACUTE KIDNEY INJURY			

subjects affected / exposed	5 / 1542 (0.32%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	1 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
CALCULUS BLADDER			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CALCULUS URINARY			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHRONIC KIDNEY DISEASE			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
CYSTITIS HAEMORRHAGIC			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
END STAGE RENAL DISEASE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
GLOMERULONEPHRITIS CHRONIC			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYDRONEPHROSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEPHROLITHIASIS			

subjects affected / exposed	3 / 1542 (0.19%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
OBSTRUCTIVE NEPHROPATHY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PELVI-URETERIC OBSTRUCTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL COLIC			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL FAILURE			
subjects affected / exposed	3 / 1542 (0.19%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	1 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
TUBULOINTERSTITIAL NEPHRITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETERIC OBSTRUCTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETEROLITHIASIS			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETHRAL STENOSIS			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY RETENTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
GOITRE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTHYROIDISM			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOTHYROIDISM			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHRITIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BACK PAIN			
subjects affected / exposed	6 / 1542 (0.39%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

BURSITIS			
subjects affected / exposed	2 / 1542 (0.13%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
COSTOCHONDRITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FASCIITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FINGER DEFORMITY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FISTULA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FOOT DEFORMITY			
subjects affected / exposed	3 / 1542 (0.19%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMARTHROSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTERVERTEBRAL DISC DISORDER			
subjects affected / exposed	0 / 1542 (0.00%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTERVERTEBRAL DISC PROTRUSION			

subjects affected / exposed	6 / 1542 (0.39%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
KNEE DEFORMITY			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LIMB DEFORMITY			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUMBAR SPINAL STENOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MORPHOEA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCLE SPASMS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYALGIA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NECK PAIN			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEOARTHRITIS			
subjects affected / exposed	22 / 1542 (1.43%)	14 / 1538 (0.91%)	
occurrences causally related to treatment / all	0 / 24	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEONECROSIS			
subjects affected / exposed	4 / 1542 (0.26%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	1 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEONECROSIS OF JAW			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEOPOROSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEOPOROTIC FRACTURE			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIARTHRITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RHEUMATOID ARTHRITIS			

subjects affected / exposed	15 / 1542 (0.97%)	12 / 1538 (0.78%)	
occurrences causally related to treatment / all	0 / 19	2 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
RHEUMATOID NODULE			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ROTATOR CUFF SYNDROME			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL OSTEOARTHRITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPONDYLOLISTHESIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SYNOVIAL CYST			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SYNOVITIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TENOSYNOVITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
ABSCCESS			

subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABSCESS LIMB			
subjects affected / exposed	0 / 1542 (0.00%)	6 / 1538 (0.39%)	
occurrences causally related to treatment / all	0 / 0	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABSCESS ORAL			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABSCESS RUPTURE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE SINUSITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANAL ABSCESS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
APPENDICITIS			
subjects affected / exposed	0 / 1542 (0.00%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHRITIS BACTERIAL			
subjects affected / exposed	6 / 1542 (0.39%)	9 / 1538 (0.59%)	
occurrences causally related to treatment / all	5 / 7	3 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHRITIS INFECTIVE			

subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASPERGILLUS INFECTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATYPICAL PNEUMONIA			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BILIARY SEPSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHITIS			
subjects affected / exposed	4 / 1542 (0.26%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	1 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHITIS VIRAL			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHOPULMONARY ASPERGILLOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BURSITIS INFECTIVE			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
CELLULITIS			

subjects affected / exposed	8 / 1542 (0.52%)	24 / 1538 (1.56%)
occurrences causally related to treatment / all	5 / 8	13 / 26
deaths causally related to treatment / all	0 / 0	0 / 0
CELLULITIS STAPHYLOCOCCAL		
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CELLULITIS STREPTOCOCCAL		
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
CERVICITIS		
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
CHRONIC TONSILLITIS		
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
CLOSTRIDIUM DIFFICILE COLITIS		
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CLOSTRIDIUM DIFFICILE INFECTION		
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
COLONIC ABSCESS		
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
DENGUE FEVER		

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE RELATED INFECTION			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE RELATED SEPSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DISSEMINATED TUBERCULOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
DIVERTICULITIS			
subjects affected / exposed	1 / 1542 (0.06%)	10 / 1538 (0.65%)	
occurrences causally related to treatment / all	1 / 1	5 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
EMPHYEMA			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENDOPHTHALMITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTERITIS INFECTIOUS			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
EPIDIDYMITIS			

subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
EPIGLOTTITIS			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ERYSIPELAS			
subjects affected / exposed	2 / 1542 (0.13%)	11 / 1538 (0.72%)	
occurrences causally related to treatment / all	3 / 4	3 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
ESCHERICHIA PYELONEPHRITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ESCHERICHIA SEPSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FUNGAL SKIN INFECTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROENTERITIS			
subjects affected / exposed	6 / 1542 (0.39%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	2 / 6	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROENTERITIS NOROVIRUS			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROENTERITIS VIRAL			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GROIN ABSCESS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATOMA INFECTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMOPHILUS SEPSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HERPANGINA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HERPES ZOSTER			
subjects affected / exposed	4 / 1542 (0.26%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	4 / 4	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTED DERMAL CYST			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTION			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTIOUS COLITIS			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTIOUS PLEURAL EFFUSION			
subjects affected / exposed	1 / 1542 (0.06%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	1 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTIVE ANEURYSM			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFLUENZA			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INJECTION SITE ABSCESS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTERVERTEBRAL DISCITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOCALISED INFECTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOWER RESPIRATORY TRACT INFECTION			

subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUDWIG ANGINA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG ABSCESS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG INFECTION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG INFECTION PSEUDOMONAL			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MASTOIDITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MENINGITIS			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCLE ABSCESS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NASAL ABSCESS			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEUROSYPHILIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OESOPHAGEAL CANDIDIASIS			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OPHTHALMIC HERPES SIMPLEX			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OPHTHALMIC HERPES ZOSTER			
subjects affected / exposed	1 / 1542 (0.06%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 1	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEOMYELITIS			
subjects affected / exposed	2 / 1542 (0.13%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	1 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEOMYELITIS CHRONIC			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OTITIS EXTERNA			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAPILLOMA VIRAL INFECTION			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIHEPATIC ABSCESS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERITONITIS			
subjects affected / exposed	0 / 1542 (0.00%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
PERITONSILLAR ABSCESS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PHARYNGITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMOCYSTIS JIROVECI PNEUMONIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
PNEUMONIA			
subjects affected / exposed	41 / 1542 (2.66%)	47 / 1538 (3.06%)	
occurrences causally related to treatment / all	18 / 46	20 / 53	
deaths causally related to treatment / all	0 / 6	4 / 8	
PNEUMONIA BACTERIAL			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
PNEUMONIA INFLUENZAL			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONIA MYCOPLASMAL			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONIA PNEUMOCOCCAL			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONIA STAPHYLOCOCCAL			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONIA VIRAL			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL INFECTION			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
POSTOPERATIVE WOUND INFECTION			
subjects affected / exposed	4 / 1542 (0.26%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PSEUDOMONAS INFECTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY TUBERCULOMA			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY TUBERCULOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYELONEPHRITIS			
subjects affected / exposed	1 / 1542 (0.06%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	0 / 1	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
RECTAL ABSCESS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RESPIRATORY TRACT INFECTION			
subjects affected / exposed	2 / 1542 (0.13%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SALPINGITIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SCROTAL ABSCESS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEPSIS			
subjects affected / exposed	7 / 1542 (0.45%)	6 / 1538 (0.39%)	
occurrences causally related to treatment / all	2 / 7	2 / 6	
deaths causally related to treatment / all	1 / 1	0 / 0	
SEPTIC SHOCK			

subjects affected / exposed	3 / 1542 (0.19%)	3 / 1538 (0.20%)	
occurrences causally related to treatment / all	3 / 4	2 / 3	
deaths causally related to treatment / all	1 / 2	2 / 3	
SINUSITIS			
subjects affected / exposed	2 / 1542 (0.13%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SOFT TISSUE INFECTION			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STAPHYLOCOCCAL INFECTION			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STAPHYLOCOCCAL SEPSIS			
subjects affected / exposed	0 / 1542 (0.00%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
STREPTOCOCCAL BACTERAEMIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBCUTANEOUS ABSCESS			
subjects affected / exposed	3 / 1542 (0.19%)	2 / 1538 (0.13%)	
occurrences causally related to treatment / all	2 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
TONGUE ABSCESS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TONSILLITIS			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TOXIC SHOCK SYNDROME STREPTOCOCCAL			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRACHEITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TUBERCULOSIS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY TRACT INFECTION			
subjects affected / exposed	12 / 1542 (0.78%)	7 / 1538 (0.46%)	
occurrences causally related to treatment / all	6 / 13	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY TRACT INFECTION BACTERIAL			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
UROSEPSIS			
subjects affected / exposed	2 / 1542 (0.13%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIRAL INFECTION			

subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIRAL PHARYNGITIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
WEST NILE VIRAL INFECTION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
WOUND INFECTION			
subjects affected / exposed	1 / 1542 (0.06%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
DEHYDRATION			
subjects affected / exposed	4 / 1542 (0.26%)	5 / 1538 (0.33%)	
occurrences causally related to treatment / all	1 / 4	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETES MELLITUS			
subjects affected / exposed	0 / 1542 (0.00%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETIC COMPLICATION			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
ELECTROLYTE IMBALANCE			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERGLYCAEMIA			

subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERKALAEMIA			
subjects affected / exposed	3 / 1542 (0.19%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOKALAEMIA			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPONATRAEMIA			
subjects affected / exposed	3 / 1542 (0.19%)	1 / 1538 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
METABOLIC ACIDOSIS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TYPE 2 DIABETES MELLITUS			
subjects affected / exposed	1 / 1542 (0.06%)	0 / 1538 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Etanercept	Tocilizumab	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	910 / 1542 (59.01%)	1090 / 1538 (70.87%)	
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	44 / 1542 (2.85%)	120 / 1538 (7.80%)	
occurrences (all)	48	156	

Vascular disorders HYPERTENSION subjects affected / exposed occurrences (all)	158 / 1542 (10.25%) 178	200 / 1538 (13.00%) 268	
Nervous system disorders HEADACHE subjects affected / exposed occurrences (all)	68 / 1542 (4.41%) 79	103 / 1538 (6.70%) 132	
Blood and lymphatic system disorders LEUKOPENIA subjects affected / exposed occurrences (all) NEUTROPENIA subjects affected / exposed occurrences (all)	21 / 1542 (1.36%) 32 33 / 1542 (2.14%) 49	85 / 1538 (5.53%) 128 92 / 1538 (5.98%) 153	
Gastrointestinal disorders DIARRHOEA subjects affected / exposed occurrences (all)	84 / 1542 (5.45%) 94	140 / 1538 (9.10%) 182	
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)	76 / 1542 (4.93%) 87	127 / 1538 (8.26%) 147	
Musculoskeletal and connective tissue disorders ARTHRALGIA subjects affected / exposed occurrences (all) BACK PAIN subjects affected / exposed occurrences (all) RHEUMATOID ARTHRITIS subjects affected / exposed occurrences (all)	106 / 1542 (6.87%) 166 92 / 1542 (5.97%) 104 132 / 1542 (8.56%) 179	143 / 1538 (9.30%) 209 147 / 1538 (9.56%) 176 152 / 1538 (9.88%) 246	
Infections and infestations BRONCHITIS subjects affected / exposed occurrences (all)	185 / 1542 (12.00%) 249	244 / 1538 (15.86%) 337	

NASOPHARYNGITIS			
subjects affected / exposed	141 / 1542 (9.14%)	239 / 1538 (15.54%)	
occurrences (all)	181	386	
PHARYNGITIS			
subjects affected / exposed	76 / 1542 (4.93%)	113 / 1538 (7.35%)	
occurrences (all)	98	146	
SINUSITIS			
subjects affected / exposed	78 / 1542 (5.06%)	88 / 1538 (5.72%)	
occurrences (all)	103	124	
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	193 / 1542 (12.52%)	243 / 1538 (15.80%)	
occurrences (all)	291	425	
URINARY TRACT INFECTION			
subjects affected / exposed	150 / 1542 (9.73%)	174 / 1538 (11.31%)	
occurrences (all)	200	243	
Metabolism and nutrition disorders			
HYPERCHOLESTEROLAEMIA			
subjects affected / exposed	52 / 1542 (3.37%)	143 / 1538 (9.30%)	
occurrences (all)	55	158	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 January 2011	<ul style="list-style-type: none">- Removal of the interim analysis- Inclusion of stroke of all classifications- "Premature withdrawal" and "Minimal telephone follow up upon withdrawal from active participation" related info were split in two different sections- Hypersensitivity reactions and Immunogenicity assessment: treatment recommendations were removed from the protocol to allow health care providers to include all therapies available according to the standard of care appropriate for the patient's reaction- Decision about monitoring compliance with home-administered etanercept to be assessed using Interactive Voice Response System (IVRS) and used syringe counts.- Revision of the process for identifying and reporting cardiovascular events for adjudication- Sponsor's decision not to collect biomarkers
21 March 2014	<ul style="list-style-type: none">- The study sample size was increased by 10% (from 2,800 to 3,080 patients) following a written recommendation from the Steering Committee- Addition of check mark for liver profile at screening in the schedule of assessments- Clarification of the non requirement for patients who withdraw from active study participation but consent to minimal follow up (e.g., annual telephone follow up) to sign a separate ICF- Treatments that are listed as "prohibited" were listed as "strongly discouraged" instead- Clear definition of the differences between (i) discontinuing study drug, (ii) discontinuing active study participation, and (iii) completely withdrawing from the study- Inclusion of additional detail to the End of Study section including description of the Common Study End Date- Inclusion of a clear indication about which assessments are required at the yearly visits for patients who have discontinued randomized treatment- Clarification about the collection requirement limited to SAEs and CV events in patients on non-randomized treatment; AEs and AESIs do not need to be collected in these patients unless they are receiving TCZ- Clarification about the fact that fully diluted Tocilizumab solutions for infusion are only stable at room temperature for a maximum of 6 hours- Volume of infusion determined by the current body weight, obtained at each visit prior to TCZ administration, rather than the last recorded body weight- Inclusion into the schedule of assessments of the following statement: subjects must have Swollen joint count (SJC) ≥ 8 (66 joint count) and tender joint count (TJC) ≥ 8 (68 joint count) during screening or at the baseline visit for enrollment

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported